Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
Balance Sheet
Inspect the capital base behind the business.
Assets
$104.23M
FY 2025 · Annual
+7.8% YoYLiabilities
$7.16M
FY 2025 · Annual
+52.5% YoYEquity
$97.07M
FY 2025 · Annual
+5.5% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $118.8M |
| Other Current | $4.4M |
| Total Current Assets | $123.2M |
| Total Assets | $123.2M |
Analysis
Selected assets total $123.2M for Latest. The largest visible component is Cash & Equivalents at $118.8M, about 96.4% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Sep 17, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 | |
| 4 | Statement of changes in beneficial ownership | Sep 15, 2026 | |
| SC 13G/A | SC 13G/A filing | Sep 11, 2026 | |
| 8-K | Current report | Sep 9, 2026 |
How much cash does TENX have?
Tenax Therapeutics, Inc. (TENX) reported $97.56M in cash and equivalents in fiscal 2025.
How much debt does TENX carry?
Tenax Therapeutics, Inc. (TENX) reported $0.00 of total debt, with net debt of -$97.56M.
Continue the stock analysis
Jump to another research area for this company.